University of Pittsburgh had begun immunization experiments in monkeys using dead polio virus. Soon, however, Salk began to test inoculations in paralyzed polio patients and by 1953 human trials among the general population were initiated. By the spring of the following year, the largest controlled field trials in medical history were underway, and by 1955 the vaccine developed by Salk and his researchers was declared effective. By 1962, Salk's vaccine had reduced the incidence of polio in the United States by 95 percent. The breakthroughs in immunology and vaccine development at Pitt by Salk and his team are considered one of the most
Jonas Salk got in. During his years at New York University Medical School, Salk worked as a laboratory technician during the school year and as a camp counselor in the summer. During Salk's medical studies, he stood out from his peers, according to Bookchin, "not just because of his continued academic prowess—he was Alpha Omega Alpha, the Phi Beta Kappa Society of medical education—but because he had decided he did not want to practice medicine." Instead, he became absorbed in research, even taking a year off to study biochemistry. He later focused more of his studies on bacteriology which had replaced medicine